)
Visual
test
Windtree Therapeutics
Windtree Therapeutics (WINT) investor relations material
Windtree Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary19 Nov, 2025
Executive summary
Net loss of $28.1 million for Q3 2025 and $42.8 million for the nine months ended September 30, 2025, with an accumulated deficit of $889.4 million as of quarter end.
Delisting from Nasdaq in August 2025 due to noncompliance with minimum bid price requirements; shares now trade on OTCID.
Shifted corporate strategy in January 2025 to focus on revenue generation through acquisitions of small companies with FDA-approved products, while continuing to seek partnerships for its cardiovascular and oncology pipeline.
Terminated the SEISMIC C clinical trial for istaroxime in severe cardiogenic shock due to resource constraints; focus shifted to less severe heart failure patients in partnership with Lee's Pharmaceutical.
Financial highlights
Q3 2025 operating loss was $19.9 million, up from $4.7 million in Q3 2024, primarily due to a $16.1 million impairment of intangible assets.
Research and development expenses for the nine months ended September 30, 2025, were $6.3 million, down from $14.1 million in the prior year period.
General and administrative expenses for the nine months ended September 30, 2025, were $5.5 million, down from $6.5 million in the prior year period.
Net cash used in operating activities was $11.4 million for the nine months ended September 30, 2025.
Cash and cash equivalents were $0.2 million as of September 30, 2025, with current liabilities of $21.9 million.
Outlook and guidance
Management believes available resources are sufficient to fund operations through December 2025, but not for 12 months from the report date, raising substantial doubt about going concern.
Plans to secure additional capital through public or private offerings, convertible debt, or strategic transactions, but none are committed.
How will new strategy impact cash runway?
Istaroxime: What is the path to Phase 3 AHF?
Funding mechanism for new acquisition strategy?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 7 FebPGIL
Strong 9MFY26 growth with 13.2% higher revenue, margin gains, and upgraded credit ratings. - 7 Feb504614
Strong revenue and profit growth in Q3 FY26, led by power and steel segments. - 7 FebCHEMPLASTS
Net losses widened and revenue fell year-over-year amid regulatory and market headwinds. - 7 FebSBIN
Q3 FY26 net profit reached ₹21,028.15 crore, driven by robust income and strategic divestments. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026.
Next Windtree Therapeutics earnings date
Q4 202515 Apr, 2026
Windtree Therapeutics
Next Windtree Therapeutics earnings date
Q4 202515 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Windtree Therapeutics Inc. is a U.S.-based biotechnology company focused on developing innovative therapies for acute cardiovascular and pulmonary conditions. The company’s pipeline includes drug candidates and technologies aimed at treating heart failure, acute respiratory distress syndrome (ARDS), and other serious cardiopulmonary diseases. Windtree’s research leverages expertise in both synthetic surfactants and precision pharmacology to address critical, unmet medical needs in hospital and critical care settings. The company is headquartered in Warrington, Pennsylvania, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage